Recombinant tissue plasminogen activator (rTPA) is the only neuroprotectant used in clinic; the limited therapeutic time window (within 4.5 h after the onset of stroke) reduces its utilization rate, leading to the result that only 3% to 8.5% of stroke patients can receive rTPA treatment [3, 4]. Here, PLAT is linked to stroke disorder.